<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02366039</url>
  </required_header>
  <id_info>
    <org_study_id>12-006665</org_study_id>
    <nct_id>NCT02366039</nct_id>
  </id_info>
  <brief_title>Probe-based Volumetric Laser Endomicroscopy (pVLE) of Endoscopic Mucosal Resection (EMR) Tissue in Patients With Barrett's Dysplasia</brief_title>
  <acronym>VLE EMR</acronym>
  <official_title>Probe-based Volumetric Laser Endomicroscopy (pVLE) of Endoscopic Mucosal Resection (EMR) Tissue in Patients With Barrett's Dysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the diagnostic accuracy and precision of the Probe-based Volumetric&#xD;
      Laser Endomicroscopy (pVLE) imaging system in detecting dysplasia in BE in both in vivo and&#xD;
      ex vivo imaging of Endoscopic Mucosal Resection (EMR) tissue, as compared to standard&#xD;
      histopathology&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the ability of pVLE to visualize subsurface architecture of EMR tissue, as compared&#xD;
      to histology in both in vivo and ex vivo imaging.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>distinguishing between normal esophageal squamous mucosa and Barrett's dysplasia</measure>
    <time_frame>at time of endoscopic mucosal resection</time_frame>
    <description>We will assess descriptive and diagnostic performance (accuracy, sensitivity, specificity, positive and negative predictive values) of the Nvision pVLE device in visualizing dysplasia as compared to standard histopathology</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Barrett's Esophagus With High Grade Dsyplasia</condition>
  <condition>Early Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>EMR</arm_group_label>
    <description>patients undergoing clinically indicated endoscopic mucosal resection as standard of care will be asked to participate for this observational study</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        subjects undergoing clinically-indicated EMR for BE dysplasia will be invited to&#xD;
        participate&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females over the age of 18 years.&#xD;
&#xD;
          2. Patients with either suspected or confirmed Barrett's-associated high grade dysplasia&#xD;
             (HGD) or intramucosal cancer (IMC) presenting for endoscopy possibly requiring EMR.&#xD;
&#xD;
          3. Ability to provide written, informed consent.&#xD;
&#xD;
          4. Females must be willing to take a pregnancy test if still capable of bearing a child.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients on anticoagulation undergoing high risk procedures in accordance to ASGE&#xD;
             guideline for the management of antithrombotic agents for endoscopic procedures&#xD;
             (2009)*.&#xD;
&#xD;
          2. Patients with esophageal varices that preclude biopsies.&#xD;
&#xD;
          3. Presence of an esophageal mass/cancer that precludes full distention of the balloon&#xD;
             from the Nvision balloon guide sheath.&#xD;
&#xD;
          4. Patients with esophageal strictures that would prevent adequate expansion of the&#xD;
             balloon from the Nvision guide sheath.&#xD;
&#xD;
          5. Patients with known inflammatory disease, esophageal tears or ulcers, which prohibit&#xD;
             full distention of the balloon from the Nvision balloon guide sheath.&#xD;
&#xD;
          6. Patients with known eosinophilic esophagitis.&#xD;
&#xD;
          7. Patients who are pregnant.&#xD;
&#xD;
          8. Patients with a history of hemostasis disorders*.&#xD;
&#xD;
               -  Patients on anticoagulation undergoing low risk procedures are not excluded. **&#xD;
                  Hemostasis disorders will include, but will not be limited to: patients with&#xD;
                  hemophilia or other congenitally acquired clotting factor deficiencies, patients&#xD;
                  with cirrhosis with coagulopathy, patients known to have thrombocytopenia&#xD;
                  (&lt;100,000 plt/ul) and individuals with von Willebrand's disease or other known&#xD;
                  platelet malfunction disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth K Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 11, 2015</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Kenneth K. Wang</investigator_full_name>
    <investigator_title>Van Cleve Professor of Gastroenterology Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

